Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Sensitive Test Enables Early Diagnosis of Rheumatoid Arthritis

By Labmedica International staff writers
Posted on 14 Dec 2011
Print article
A highly sensitive and specific laboratory test enables the early diagnosis of rheumatoid arthritis (RA), which in turn allows for successful treatment of this autoimmune disease.

The new Anti-CCP hs (high sensitive) test is the most recent development in the area of anticitrullinated peptide antibody (ACPA) testing. This innovative enzyme immunoassay combines the advantages of mutated citrullinated vimentin (MCV) antibody detection (anti-MCV), with the power of modern peptide synthesis. It an effective tool for the rapid and precise routine diagnosis of suspected RA and the diagnosis of early rheumatoid arthritis.

In combination with medical history, clinical observations, and imaging techniques, serological tests like Anti-CCP hs are the basis for early diagnosis of RA. Early diagnosis is critical to patient outcomes because early, effective treatment can avert damage to the joints and maintain their function.

Orgentec Diagnostika (Mainz, Germany) developed the Anti-CCP hs test; it also develops and markets test systems for autoimmune diagnostics and serological tests for infectious disease. Orgentec has developed numerous highly specific ELISA test systems, immunoblot and immunofluorescence tests, the Alegria random access analyzer, and the rheumachec rapid test.

Related Links:
Orgentec Diagnostika


Print article

Channels

Genetic Tests

view channel
Image: The BioMek FXP automation workstation (Photo courtesy of Beckman Coulter).

Innovative Gene Testing Technology Finds Cancer Risks

A new method has been developed for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate,... Read more

Industry News

view channel

Luminex Enters Agreement to Acquire Nanosphere

Luminex Corporation (Austin, TX, USA) and Nanosphere, Inc. (Northbrook, IL, USA) have entered into a definitive agreement under which Luminex will acquire Nanosphere, a leader in molecular microbiology and diagnostics, in an all-cash transaction valued at approximately USD 77 million (USD 1.70 per share).... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.